These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 7530749

  • 1. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.
    Takeshita T, Takahashi H, Kozlowski S, Ahlers JD, Pendleton CD, Moore RL, Nakagawa Y, Yokomuro K, Fox BS, Margulies DH.
    J Immunol; 1995 Feb 15; 154(4):1973-86. PubMed ID: 7530749
    [Abstract] [Full Text] [Related]

  • 2. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S.
    J Pept Sci; 1995 Feb 15; 1(2):109-23. PubMed ID: 9222988
    [Abstract] [Full Text] [Related]

  • 3. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.
    Shirai M, Pendleton CD, Berzofsky JA.
    J Immunol; 1992 Mar 15; 148(6):1657-67. PubMed ID: 1371784
    [Abstract] [Full Text] [Related]

  • 4. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition.
    Boehncke WH, Takeshita T, Pendleton CD, Houghten RA, Sadegh-Nasseri S, Racioppi L, Berzofsky JA, Germain RN.
    J Immunol; 1993 Jan 15; 150(2):331-41. PubMed ID: 8093457
    [Abstract] [Full Text] [Related]

  • 5. Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells.
    Leighton J, Sette A, Sidney J, Appella E, Ehrhardt C, Fuchs S, Adorini L.
    J Immunol; 1991 Jul 01; 147(1):198-204. PubMed ID: 1711074
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A molecular basis for how a single TCR interfaces multiple ligands.
    Boesteanu A, Brehm M, Mylin LM, Christianson GJ, Tevethia SS, Roopenian DC, Joyce S.
    J Immunol; 1998 Nov 01; 161(9):4719-27. PubMed ID: 9794402
    [Abstract] [Full Text] [Related]

  • 8. The T/B cell interaction involved in induction of the mouse IgG2ab suppression is restricted by major histocompatibility complex class I, but not class II molecules.
    Majlessi L, Bordenave G.
    Eur J Immunol; 1997 Jun 01; 27(6):1346-52. PubMed ID: 9209483
    [Abstract] [Full Text] [Related]

  • 9. Preferential V beta usage by cytotoxic T cells cross-reactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction.
    Shirai M, Vacchio MS, Hodes RJ, Berzofsky JA.
    J Immunol; 1993 Aug 15; 151(4):2283-95. PubMed ID: 7688397
    [Abstract] [Full Text] [Related]

  • 10. Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo.
    Shen X, Hu B, McPhie P, Wu X, Fox A, Germain RN, König R.
    J Immunol; 1996 Jul 01; 157(1):87-100. PubMed ID: 8683160
    [Abstract] [Full Text] [Related]

  • 11. Permissive recognition of a mycobacterial T-cell epitope: localization of overlapping epitope core sequences recognized in association with multiple major histocompatibility complex class II I-A molecules.
    Harris DP, Vordermeier HM, Arya A, Moreno C, Ivanyi J.
    Immunology; 1995 Apr 01; 84(4):555-61. PubMed ID: 7790029
    [Abstract] [Full Text] [Related]

  • 12. Degenerate MHC restriction reveals the contribution of class I MHC molecules in determining the fine specificity of CTL recognition of an immunodominant determinant of HIV-1 gp160 V3 loop.
    Shirai M, Kozlowski S, Margulies DH, Berzofsky JA.
    J Immunol; 1997 Apr 01; 158(7):3181-8. PubMed ID: 9120272
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
    Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA.
    J Immunol; 1994 Jan 15; 152(2):549-56. PubMed ID: 8283036
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CD4+ class I-restricted T cells specific for HIV gp160 315-329.
    Moore RL, Fox BS.
    Cell Immunol; 1994 Mar 15; 154(1):43-53. PubMed ID: 7907008
    [Abstract] [Full Text] [Related]

  • 17. Human immunodeficiency virus-1 reverse transcriptase immunodominant CD4+ T cell epitopes: a peptide-based multiparametric assessment in the mouse.
    Borg JP, Ihlenfeldt HG, Jung G, Haas G, Pierres M.
    Eur J Immunol; 1994 Jul 15; 24(7):1496-502. PubMed ID: 7517871
    [Abstract] [Full Text] [Related]

  • 18. MUC1 peptide epitopes associated with five different H-2 class I molecules.
    Apostolopoulos V, Haurum JS, McKenzie IF.
    Eur J Immunol; 1997 Oct 15; 27(10):2579-87. PubMed ID: 9368613
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes.
    Gregori S, Trembleau S, Penna G, Gallazzi F, Hammer J, Papadopoulos GK, Adorini L.
    J Immunol; 1999 Jun 01; 162(11):6630-40. PubMed ID: 10352280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.